Arovella Therapeutics Limited ASX: ALA Share Price & Review

ALA Overview

ALA Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Weak

GARP

Very Weak

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Weak

Growth

Earnings

Very Weak

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About ALA

Website

N/A

Telephone

61.3.9824.5254

Address

Level 3, Suite 1 62 Lygon Street Carlton South, Victoria (VIC) 3053

Description

Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.

ALA Price Chart

Key Stats

Market Cap

AU$94.49M

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.07 - 0.21

Trade Value (12mth)

AU$51,445.00

1 week

1 month

-15.96%

YTD

-53.53%

1 year

-47.33%

All time high

14.78

Key Fundamentals

EPS 3 yr Growth

-56.70%

EBITDA Margin

Operating Cashflow

-$7m

Free Cash Flow Return

-44.30%

ROIC

-48.00%

Interest Coverage

N/A

Quick Ratio

14.20

Other Data

Shares on Issue (Fully Dilluted)

1108m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ALA Announcements

Latest Announcements

Date	Announcements
11 September 25	2025 ESG Report × 2025 ESG Report
05 September 25	S&P DJI Announces September 2025 Quarterly Rebalance × S&P DJI Announces September 2025 Quarterly Rebalance
03 September 25	Notification of Date of 2025 AGM × Notification of Date of 2025 AGM
28 August 25	US Patent to be granted for iNKT Cell Therapy Platform × US Patent to be granted for iNKT Cell Therapy Platform
25 August 25	Application for quotation of securities - ALA × Application for quotation of securities - ALA
25 August 25	Notice Under Section 708A × Notice Under Section 708A
22 August 25	Appendix 4E and Annual Report × Appendix 4E and Annual Report
22 August 25	Appendix 4G × Appendix 4G
22 August 25	Corporate Governance Statement × Corporate Governance Statement
07 August 25	Application for quotation of securities - ALA × Application for quotation of securities - ALA
07 August 25	Notice Under Section 708A × Notice Under Section 708A
04 August 25	Application for quotation of securities - ALA × Application for quotation of securities - ALA
04 August 25	Notice Under Section 708A × Notice Under Section 708A
01 August 25	Proposed issue of securities - ALA × Proposed issue of securities - ALA
28 July 25	Quarterly Activities/Appendix 4C Cash Flow Report × Quarterly Activities/Appendix 4C Cash Flow Report
28 July 25	Investor Presentation × Investor Presentation
16 July 25	Notification regarding unquoted securities - ALA × Notification regarding unquoted securities - ALA
07 July 25	Notification of cessation of securities - ALA × Notification of cessation of securities - ALA
02 July 25	Investor Presentation × Investor Presentation
01 July 25	Final Director's Interest Notice × Final Director's Interest Notice
30 June 25	Retirement of Non-Executive Chairman × Retirement of Non-Executive Chairman
30 June 25	Notice Under Section 708A × Notice Under Section 708A
27 June 25	Application for quotation of securities - ALA × Application for quotation of securities - ALA
24 June 25	Notice Under Section 708A × Notice Under Section 708A
23 June 25	Application for quotation of securities - ALA × Application for quotation of securities - ALA

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Falling Divs over next 2

Values and Recommendations

Key Stats

Consensus Score

Recommendation

EPS 1 month Change

Quality Yield

Falling Divs over next 2

Halo Consensus Score

PEG Ratio

Consensus EPS Revisions

Short selling

Key Stats

Percent of Issue

0.01%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ALA Shortsell

Frequently Asked Questions

What is the current share price of Arovella Therapeutics Limited (ALA:ASX)?

The current share price of Arovella Therapeutics Limited (ALA:ASX) is AU$0.084.

What is the 52-week high share price for Arovella Therapeutics Limited (ALA:ASX)?

The 52-week high share price for Arovella Therapeutics Limited (ALA:ASX) is AU$0.21.

What is the 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)?

The 52-week low share price for Arovella Therapeutics Limited (ALA:ASX)? is AU$0.07.

What is the dividend yield for Arovella Therapeutics Limited (ALA:ASX)?

Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.

What was Arovella Therapeutics Limited (ALA:ASX) last dividend payment?

Arovella Therapeutics Limited (ALA:ASX) does not pay a dividend.

What is the franking level for Arovella Therapeutics Limited (ALA:ASX)?

Arovella Therapeutics Limited (ALA:ASX) has a franking level of 0.0%.

In which sector is Arovella Therapeutics Limited (ALA:ASX) classified?

Arovella Therapeutics Limited (ALA:ASX) is classified in the Healthcare.

The current P/E ratio for Arovella Therapeutics Limited (ALA:ASX) is .